Hypermarcas (OTCMKTS:HYPMY) Sees Large Volume Increase – Still a Buy?

Shares of Hypermarcas (OTCMKTS:HYPMY) saw strong trading volume on Tuesday. Approximately 102,494 shares were traded during trading, an increase of 117% from the previous session’s volume of 47,293 shares. The stock last traded at $5.36 and had previously closed at $5.14.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Hypermarcas Trading Up 5.1%

The firm has a market capitalization of $3.80 billion, a price-to-earnings ratio of 10.80 and a beta of 0.65. The firm’s 50 day moving average is $4.58 and its 200 day moving average is $4.41. The company has a quick ratio of 1.26, a current ratio of 1.86 and a debt-to-equity ratio of 0.50.

Hypermarcas (OTCMKTS:HYPMY) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a net margin of 19.77% and a return on equity of 12.68%. Equities analysts forecast that Hypermarcas will post 0.51 earnings per share for the current year.

About Hypermarcas

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.